Header Logo

Connection

CHARLES WYKOFF to Treatment Outcome

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Treatment Outcome.
CHARLES WYKOFF
Connection Strength
1.634
Treatment Outcome
  1. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE. Am J Ophthalmol. 2025 Aug; 276:350-364.
    View in: PubMed
    Score: 0.076
  2. Sozinibercept Combination Therapy for Neovascular Age-related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type. Ophthalmic Surg Lasers Imaging Retina. 2025 May; 56(5):287-296.
    View in: PubMed
    Score: 0.075
  3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials. Ophthalmology. 2024 Jun; 131(6):708-723.
    View in: PubMed
    Score: 0.069
  4. KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema. Am J Ophthalmol. 2024 04; 260:70-83.
    View in: PubMed
    Score: 0.067
  5. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 02 19; 399(10326):741-755.
    View in: PubMed
    Score: 0.061
  6. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 03; 235:131-142.
    View in: PubMed
    Score: 0.059
  7. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes. Am J Ophthalmol. 2021 06; 226:126-136.
    View in: PubMed
    Score: 0.057
  8. Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2019 09 01; 50(9):e250-e256.
    View in: PubMed
    Score: 0.051
  9. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol Retina. 2019 12; 3(12):1076-1086.
    View in: PubMed
    Score: 0.051
  10. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019 Aug; 97(5):460-472.
    View in: PubMed
    Score: 0.049
  11. Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes. Graefes Arch Clin Exp Ophthalmol. 2019 May; 257(5):883-889.
    View in: PubMed
    Score: 0.049
  12. Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):692-697.
    View in: PubMed
    Score: 0.048
  13. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
    View in: PubMed
    Score: 0.046
  14. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017 Jan; 173:56-63.
    View in: PubMed
    Score: 0.042
  15. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
    View in: PubMed
    Score: 0.041
  16. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.039
  17. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.035
  18. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep; 120(9):1945-6.e1.
    View in: PubMed
    Score: 0.034
  19. Anti-vascular endothelial growth factor agents for pediatric retinal diseases. Int Ophthalmol Clin. 2011; 51(1):185-99.
    View in: PubMed
    Score: 0.028
  20. Fovea-sparing retinal detachments: time to surgery and visual outcomes. Am J Ophthalmol. 2010 Aug; 150(2):205-210.e2.
    View in: PubMed
    Score: 0.027
  21. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology. 2008 Sep; 115(9):1501-7, 1507.e1-2.
    View in: PubMed
    Score: 0.023
  22. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR STAGES 3 AND 4 PROLIFERATIVE SICKLE CELL RETINOPATHY RESULTS IN IMPROVED ANATOMICAL AND VISUAL OUTCOMES. Retina. 2026 Jan 01; 46(1):171-178.
    View in: PubMed
    Score: 0.020
  23. IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study. Retina. 2025 Dec 01; 45(12):2252-2262.
    View in: PubMed
    Score: 0.020
  24. Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study. Ophthalmic Surg Lasers Imaging Retina. 2025 Jul; 56(7):398-406.
    View in: PubMed
    Score: 0.019
  25. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. JAMA Ophthalmol. 2025 Apr 01; 143(4):317-325.
    View in: PubMed
    Score: 0.019
  26. Outcomes of Eyes Undergoing Silicone Oil Removal Following Complex Rhegmatogenous Retinal Detachment Repair. Clin Exp Ophthalmol. 2025 Aug; 53(6):637-644.
    View in: PubMed
    Score: 0.019
  27. MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2025 Feb; 132(2):131-140.
    View in: PubMed
    Score: 0.018
  28. Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration. Can J Ophthalmol. 2025 Feb; 60(1):e92-e99.
    View in: PubMed
    Score: 0.018
  29. MANAGEMENT OF LARGE FULL-THICKNESS MACULAR HOLES: Long-Term Outcomes of Internal Limiting Membrane Flaps and Internal Limiting Membrane Peels. Retina. 2024 07 01; 44(7):1165-1170.
    View in: PubMed
    Score: 0.018
  30. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024 04 20; 403(10436):1563-1573.
    View in: PubMed
    Score: 0.018
  31. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 03 23; 403(10432):1153-1163.
    View in: PubMed
    Score: 0.018
  32. Safety and Efficacy of CLS-TA by Anatomic Location of Inflammation: Results from the Phase 3 PEACHTREE Clinical Trial. Ocul Immunol Inflamm. 2024 Oct; 32(8):1556-1563.
    View in: PubMed
    Score: 0.017
  33. Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial. JAMA Ophthalmol. 2023 12 01; 141(12):1152-1160.
    View in: PubMed
    Score: 0.017
  34. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial. Ophthalmol Retina. 2024 Feb; 8(2):116-125.
    View in: PubMed
    Score: 0.017
  35. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21; 402(10411):1449-1458.
    View in: PubMed
    Score: 0.017
  36. Surgical Management of Full-Thickness Macular Holes in Macular Telangiectasia Type 2: A Global Multicenter Study. Ophthalmology. 2024 Jan; 131(1):66-77.
    View in: PubMed
    Score: 0.017
  37. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 07; 130(7):735-747.
    View in: PubMed
    Score: 0.016
  38. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023 06; 130(6):588-597.
    View in: PubMed
    Score: 0.016
  39. Scleral Buckling Alone or in Combination with Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Repair: A Meta-Analysis of 7,212 Eyes. Ophthalmologica. 2022; 245(4):296-314.
    View in: PubMed
    Score: 0.015
  40. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 09; 129(9):974-985.
    View in: PubMed
    Score: 0.015
  41. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022 Sep-Oct; 67(5):1346-1363.
    View in: PubMed
    Score: 0.015
  42. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023 01; 37(1):6-16.
    View in: PubMed
    Score: 0.015
  43. Clinical impact of the worldwide shortage of verteporfin (Visudyne?) on ophthalmic care. Acta Ophthalmol. 2022 Nov; 100(7):e1522-e1532.
    View in: PubMed
    Score: 0.015
  44. Pars plana vitrectomy versus scleral buckle: A comprehensive meta-analysis of 15,947 eyes. Surv Ophthalmol. 2022 Jul-Aug; 67(4):932-949.
    View in: PubMed
    Score: 0.015
  45. Supplemental Scleral Buckle for the Management of Rhegmatogenous Retinal Detachment by Pars Plana Vitrectomy: A Meta-Analysis of Randomized Controlled Trials. Ophthalmologica. 2022; 245(2):101-110.
    View in: PubMed
    Score: 0.015
  46. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. Am J Ophthalmol. 2022 04; 236:12-19.
    View in: PubMed
    Score: 0.015
  47. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 01; 139(9):946-955.
    View in: PubMed
    Score: 0.015
  48. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2021 07; 128(7):1027-1038.
    View in: PubMed
    Score: 0.014
  49. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study. Ophthalmol Retina. 2021 01; 5(1):60-70.
    View in: PubMed
    Score: 0.014
  50. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020 08 01; 138(8):851-857.
    View in: PubMed
    Score: 0.014
  51. Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
    View in: PubMed
    Score: 0.014
  52. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.013
  53. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020 10; 127(10):1331-1344.
    View in: PubMed
    Score: 0.013
  54. THE TEXAS TACO TECHNIQUE FOR INTERNAL LIMITING MEMBRANE FLAP IN LARGE FULL-THICKNESS MACULAR HOLES: A Short-Term Pilot Study. Retina. 2020 Mar; 40(3):552-556.
    View in: PubMed
    Score: 0.013
  55. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020 09; 127(9):1179-1188.
    View in: PubMed
    Score: 0.013
  56. Intravitreal Combined Aflibercept?+ Anti-Platelet-Derived Growth Factor Receptor ? for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 02; 127(2):211-220.
    View in: PubMed
    Score: 0.013
  57. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye (Lond). 2020 03; 34(3):480-490.
    View in: PubMed
    Score: 0.013
  58. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.012
  59. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.012
  60. Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes. Am J Ophthalmol. 2012 Jan; 153(1):162-6.e1.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.